Clinical Trials Logo

Filter by:
NCT ID: NCT01256723 Active, not recruiting - Clinical trials for Coronary Artery Disease

Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents

J-LESSON
Start date: October 2010
Phase: N/A
Study type: Observational

The main purpose of this study is to observe the incidence of major adverse cardiac and cerebrovascular events (MACCE), target vessel failure (TVF), target vessel revascularization (TVR) and stent thrombosis out to 5 years after the procedure in patients who underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents for unprotected left main coronary artery (ULMCA) disease and lesions involving the ULMCA in Japan. The investigators will also establish a method of adjustment to the Japanese version of the SYNTAX score by conducting an assessment using the SYNTAX score recently reported in the US and Europe as well as the EuroSCORE, and by clarifying the differences of PCI procedures and treatment results in Japan with those reported in the US and Europe.

NCT ID: NCT01227772 Active, not recruiting - Gastric Cancer Clinical Trials

Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer

Start date: November 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Active vaccination with tumor specific antigens and VEGFR1 HLA-A24 epitopes can improve survival of patients with advanced Gastric Cancer.

NCT ID: NCT01227239 Active, not recruiting - Rectal Carcinoma Clinical Trials

Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting

Start date: September 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study. The purpose of this study is as follows, - In phase I, to determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). - In phase II, to evaluate the antitumor effect (pCR rate) and the safety .

NCT ID: NCT01226316 Active, not recruiting - Ovarian Cancer Clinical Trials

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Start date: December 1, 2010
Phase: Phase 1
Study type: Interventional

This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future. This study will also investigate how the body handles AZD5363 (ie, how quickly the body absorbs and removes the drug). This study will also investigate anti-tumour activity of AZD5363 in patients with advanced / metastatic breast, gynaecological cancers or other solid cancers bearing either AKT1 / PIK3CA or PTEN mutation.

NCT ID: NCT01225471 Active, not recruiting - Prostate Cancer Clinical Trials

Novel Peptide Vaccination for Patients With Advanced Prostate Cancer

Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical efficacy of novel peptide vaccination for advanced prostate cancer

NCT ID: NCT01217034 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib

TACTICS
Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical resection or percutaneous ablation therapy.

NCT ID: NCT01157481 Active, not recruiting - Clinical trials for Diastolic Heart Failure

Diastolic Heart Failure Management by Nifedipine

DEMAND
Start date: July 2010
Phase: N/A
Study type: Interventional

Patients with heart failure with preserved ejection fraction have a equally high risk for mortality and re-hospitalization as those with reduced ejection fraction. Effective management strategies are critically needed to be established for this type of heart failure. These patients have more hypertensive and ischemic etiology than those with reduced ejection fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the heart failure clinical composite response endpoint compared with the conventional treatment in patients with heart failure with hypertension and/or coronary artery disease and preserved ejection fraction (>=50%) by echocardiography. This study is multi-center, prospective, randomized, open-label, and blinded-endpoint design.

NCT ID: NCT01150500 Active, not recruiting - Clinical trials for Coronary Artery Disease

RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries

RJ-SVS
Start date: June 2010
Phase: N/A
Study type: Interventional

The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.

NCT ID: NCT01123681 Active, not recruiting - Critical Illness Clinical Trials

Intubation and Extubation Over 48 Hours Mechanical Ventilation

INDEX48
Start date: May 2010
Phase: N/A
Study type: Observational

The purpose of this study is to determine how often ventilator associated pneumonia happens in the current intensive care units, and how types of endotracheal tube affect its occurrence.

NCT ID: NCT01101451 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Start date: April 12, 2010
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.